Agah Ramtin Insider Trading Activity

Average Profitability
12.75%
Insider Buys Quantity
6
Insider Buys Sum
$135,739.52
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Agah Ramtin

According to the SEC Form 4 filings, Agah Ramtin, being in a position of

  1. Chief Medical Officer at RenovoRx, Inc.,
    оver the last 12 months, has bought 64000 shares for $55,968, and sold 0 shares,
    over all time since 2022-06-07, has bought 222165 shares for $221,108, and sold 0 shares.

Biography of Agah Ramtin

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$55,9687100
Sells
$000

Comparison of Insiders on Amount of Buys and Sells

2026-01-21PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
10,000
0.0273%
$1.00$9,975-2.61%
2025-12-31PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
9,795
0.0263%
$0.86$8,424+16.65%
2025-12-30PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
205
0.0005%
$0.83$169+11.96%
2025-12-16PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
12,000
0.033%
$0.85$10,200+15.11%
2025-12-05PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
10,000
0.0278%
$0.96$9,600+3.05%
2025-11-24PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
12,000
0.0329%
$0.80$9,600+22.75%
2025-11-21PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
10,000
0.0274%
$0.80$8,000+21.18%
2025-06-05PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
21,000
0.0574%
$1.40$29,400-28.57%
2025-04-15PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
15,000
0.0468%
$0.90$13,500+15.56%
2025-04-11PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
20,000
0.0554%
$0.80$16,000+34.72%
2025-04-09PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
30,000
0.0845%
$0.81$24,399+25.3%
2025-04-08PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
26,000
0.0756%
$0.84$21,840+30%
2024-01-26PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
40,983
0.4453%
$1.22$49,999+15.24%
2022-06-07PurchaseRenovoRx, Inc.
RNXT
Chief Medical Officer
5,182
0.0566%
$1.93$10,001+10.26%
Total: 14
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.